BioCentury | Feb 11, 2008
Company News

Indivumed management update

...Germany Business: Cancer, Supply/Service Hired: Harald Eistetter as CBO and managing director, formerly CEO of The Genetics Co. Inc. WIR...
BioCentury | Jan 9, 2006
Finance

Money & milestones

...II Diatos Series B 2/25/04 $39.4 Ph II elbion Series A 5/24/05 $45.3 Ph II Genetics Co....
BioCentury | May 23, 2005
Company News

Genetics Co., Prodotti Gianni s.p.a sales and marketing update

...Prodotti received Italian distribution rights to Genetics Co.'s Alzheimer's disease (AD) diagnostics and research tools. The Genetics Co. Inc....
BioCentury | Feb 21, 2005
Finance

Ebb & Flow

...but Topper noted that most of the validation data are in cardiovascular diseases. In Switzerland, Genetics Co....
BioCentury | Feb 16, 2005
Financial News

Genetics Co. raises CHF25 million

...CHF17 million and a second tranche of CHF8 million, which is dependent on clinical milestones. Genetics Co....
BioCentury | Aug 9, 2004
Company News

NeoPharm, Nippon Genetics Co. Ltd. sales and marketing update

...rights to NEOL's NeoPhectin line of transfection reagents. NeoPharm Inc. (NEOL), Lake Forest, Ill. Nippon Genetics Co....
BioCentury | Apr 5, 2004
Company News

Morphochem, Genetics Co. deal

...use its MOREsystem structural biology tools to generate biostructural information on compounds supplied by The Genetics Co....
...are beta-Secretase inhibitors for the treatment of Alzheimer's disease (AD). Morphochem AG , Munich, Germany The Genetics Co. Inc....
BioCentury | Jun 23, 2003
Company News

Abeta GmbH, Genetics Co. deal

...and a target involved in the amyloid precursor protein pathway. Abeta GmbH , Heidelberg, Germany The Genetics Co. Inc....
BioCentury | Jun 16, 2003
Company News

Genetics Co. acquires Abeta assets

Genetics Co. (Schlieren, Switzerland) acquired the assets of Abeta (Heidelberg, Germany), which focuses on diagnostics and therapeutics for Alzheimer's Disease (AD). The cash and stock purchase includes technology and assays for detecting cellular amyloid-beta peptide...
BioCentury | Jan 27, 2003
Company News

Genetics Co. management update

...The Genetics Co. Inc. , Schlieren, Switzerland Business: Cancer, Autoimmune/Inflammation, Chemistry Hired: Dietmar Gundel as VP of...
Items per page:
1 - 10 of 16
BioCentury | Feb 11, 2008
Company News

Indivumed management update

...Germany Business: Cancer, Supply/Service Hired: Harald Eistetter as CBO and managing director, formerly CEO of The Genetics Co. Inc. WIR...
BioCentury | Jan 9, 2006
Finance

Money & milestones

...II Diatos Series B 2/25/04 $39.4 Ph II elbion Series A 5/24/05 $45.3 Ph II Genetics Co....
BioCentury | May 23, 2005
Company News

Genetics Co., Prodotti Gianni s.p.a sales and marketing update

...Prodotti received Italian distribution rights to Genetics Co.'s Alzheimer's disease (AD) diagnostics and research tools. The Genetics Co. Inc....
BioCentury | Feb 21, 2005
Finance

Ebb & Flow

...but Topper noted that most of the validation data are in cardiovascular diseases. In Switzerland, Genetics Co....
BioCentury | Feb 16, 2005
Financial News

Genetics Co. raises CHF25 million

...CHF17 million and a second tranche of CHF8 million, which is dependent on clinical milestones. Genetics Co....
BioCentury | Aug 9, 2004
Company News

NeoPharm, Nippon Genetics Co. Ltd. sales and marketing update

...rights to NEOL's NeoPhectin line of transfection reagents. NeoPharm Inc. (NEOL), Lake Forest, Ill. Nippon Genetics Co....
BioCentury | Apr 5, 2004
Company News

Morphochem, Genetics Co. deal

...use its MOREsystem structural biology tools to generate biostructural information on compounds supplied by The Genetics Co....
...are beta-Secretase inhibitors for the treatment of Alzheimer's disease (AD). Morphochem AG , Munich, Germany The Genetics Co. Inc....
BioCentury | Jun 23, 2003
Company News

Abeta GmbH, Genetics Co. deal

...and a target involved in the amyloid precursor protein pathway. Abeta GmbH , Heidelberg, Germany The Genetics Co. Inc....
BioCentury | Jun 16, 2003
Company News

Genetics Co. acquires Abeta assets

Genetics Co. (Schlieren, Switzerland) acquired the assets of Abeta (Heidelberg, Germany), which focuses on diagnostics and therapeutics for Alzheimer's Disease (AD). The cash and stock purchase includes technology and assays for detecting cellular amyloid-beta peptide...
BioCentury | Jan 27, 2003
Company News

Genetics Co. management update

...The Genetics Co. Inc. , Schlieren, Switzerland Business: Cancer, Autoimmune/Inflammation, Chemistry Hired: Dietmar Gundel as VP of...
Items per page:
1 - 10 of 16